LongeVC

LongeVC is a venture capital firm specializing in early-stage investments in biotechnology, with a strong focus on longevity and age-related innovations. Based in Lugano, Switzerland, and Latvia, the firm targets breakthrough startups in sectors like biotech, life sciences, and therapeutics that aim to extend human health and longevity. LongeVC typically invests between €0.5 million and €2.3 million in companies across Europe, the U.S., and Israel. The firm is backed by a deep scientific advisory board and meticulously prioritizes scientific due diligence. Their portfolio includes leading biotech startups such as Insilico Medicine, known for AI-driven drug discovery, and Longenesis, which provides tools for collaborative biotech research. LongeVC's mission is to bring life-changing health technologies to market, addressing global challenges like aging and healthcare. Led by partners like Ilya Suharenko and Garri Zmudze, LongeVC offers not only capital but also strategic business development support, helping founders build scalable businesses that can make a global impact.